ExpreS2ion Biotech Holding AB (EXPRS2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has a cash flow conversion efficiency ratio of -0.965x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-25.49 Million ≈ $-2.74 Million USD) by net assets (Skr26.42 Million ≈ $2.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EXPRS2 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
ExpreS2ion Biotech Holding AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ExpreS2ion Biotech Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioSenic S.A.
BR:BIOS
|
0.059x |
|
Fitness Champs Holdings Limited Common Stock
NASDAQ:FCHL
|
0.100x |
|
Prosper Gold Corp.
V:PGX
|
-0.028x |
|
CFI-Compagnie Foncière Internationale
PA:CFI
|
0.135x |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
|
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
-0.760x |
|
Golden Cross Resources Ltd
AU:GCR
|
-0.046x |
|
BlackRock Latin American Investment Trust plc
LSE:BRLA
|
0.074x |
Annual Cash Flow Conversion Efficiency for ExpreS2ion Biotech Holding AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of ExpreS2ion Biotech Holding AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see ExpreS2ion Biotech Holding AB market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr35.69 Million ≈ $3.84 Million |
Skr-40.90 Million ≈ $-4.40 Million |
-1.146x | -117.64% |
| 2024-12-31 | Skr64.42 Million ≈ $6.93 Million |
Skr-33.93 Million ≈ $-3.65 Million |
-0.527x | +65.88% |
| 2023-12-31 | Skr65.36 Million ≈ $7.03 Million |
Skr-100.89 Million ≈ $-10.86 Million |
-1.543x | -60.10% |
| 2022-12-31 | Skr103.33 Million ≈ $11.12 Million |
Skr-99.61 Million ≈ $-10.72 Million |
-0.964x | -196.42% |
| 2021-12-31 | Skr140.35 Million ≈ $15.10 Million |
Skr-45.65 Million ≈ $-4.91 Million |
-0.325x | -69.19% |
| 2020-12-31 | Skr94.55 Million ≈ $10.17 Million |
Skr-18.18 Million ≈ $-1.96 Million |
-0.192x | -101.63% |
| 2019-12-31 | Skr-1.08 Million ≈ $-116.12K |
Skr-12.69 Million ≈ $-1.37 Million |
11.762x | +858.09% |
| 2018-12-31 | Skr8.30 Million ≈ $893.32K |
Skr-12.88 Million ≈ $-1.39 Million |
-1.551x | -21.43% |
| 2017-12-31 | Skr6.74 Million ≈ $725.01K |
Skr-8.61 Million ≈ $-926.36K |
-1.278x | -134.40% |
| 2016-12-31 | Skr12.88 Million ≈ $1.39 Million |
Skr-7.02 Million ≈ $-755.57K |
-0.545x | -- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more